What's Happening?
Lundbeck has presented new data from the INFUSE study at the American Academy of Neurology 2026 Annual Meeting, highlighting improvements in cognitive symptoms among migraine patients treated with VYEPTI (eptinezumab-jjmr). The study observed patient-reported
outcomes over six months, focusing on cognitive issues like brain fog and decision-making difficulties. The findings indicate that more than 50% of participants reported improvements in these symptoms after receiving VYEPTI, a preventive migraine treatment administered via IV infusion. The study emphasizes the importance of addressing the broader burden of migraine, beyond just headache frequency, to improve patients' quality of life.
Why It's Important?
Migraine is a debilitating condition affecting over 40 million people in the U.S., with significant impacts on daily life and productivity. The INFUSE study's findings are crucial as they provide real-world evidence of the benefits of VYEPTI in managing cognitive symptoms associated with migraines. This could lead to more comprehensive treatment approaches that address the full spectrum of migraine-related issues, potentially improving outcomes for patients who have not responded to other treatments. The study also reinforces the need for personalized treatment plans that consider individual patient needs and symptoms.
What's Next?
The results from the INFUSE study may influence clinical practices by encouraging healthcare providers to consider cognitive symptoms when prescribing migraine treatments. Lundbeck plans to continue its research to further understand the holistic impact of VYEPTI on migraine patients. Future studies may explore the long-term effects of VYEPTI and its potential to improve other aspects of migraine-related disability. Additionally, the findings could prompt further investigation into the mechanisms by which VYEPTI alleviates cognitive symptoms, potentially leading to new therapeutic targets.
